References
- Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111–188. doi: 10.1093/eurheartj/ehz455. Erratum in: Eur Heart J. 2020 Nov 21;41(44):4255. PMID: 31504418.
- Mendes P, Robles PG, Mathur S. Statin-induced rhabdomyolysis: a comprehensive review of case reports. Physiother Can. 2014;66(2):124–132. doi:10.3138/ptc.2012-65
- Ezad S, Cheema H, Collins N. Statin-induced rhabdomyolysis: a complication of a commonly overlooked drug interaction. Oxf Med Case Reports. 2018;2018(3):omx104. Published 2018 Mar 14. doi:10.1093/omcr/omx104
- Mohamed MFH, Salameh OK, Saeed AAM. Statin-Induced Rhabdomyolysis, Acute Kidney Injury, and Hepatitis Leading to Death. Am J Case Rep. 2019 May 18;20:709–712. doi: 10.12659/AJCR.914707. PMID: 31101801; PMCID: PMC6537756.
- Ward NC, Watts GF, Eckel RH. Statin Toxicity. Circ Res. 2019 Jan 18;124(2):328–350. doi: 10.1161/CIRCRESAHA.118.312782. PMID: 30653440.
- Sabatine MS. PCSK9 inhibitors: clinical evidence and implementation. Nat Rev Cardiol. 2019 Mar;16(3):155–165. doi: 10.1038/s41569-018-0107-8. PMID: 30420622.
- Tobert JA, Newman CB. The nocebo effect in the context of statin intolerance. J Clin Lipidol. 2016 Jul–Aug;10(4):739–747. doi: 10.1016/j.jacl.2016.05.002. Epub 2016 May 13. PMID: 27578103.
- Mammen AL. Statin-Associated Autoimmune Myopathy. N Engl J Med. 2016 Feb 18;374(7):664–9. doi: 10.1056/NEJMra1515161. PMID: 26886523.
- Gallo A, Perregaux J, Bruckert E. Advances in the management of statin myopathy. Curr Opin Endocrinol Diabetes Obes. 2021 Apr 1;28(2):142–151. doi: 10.1097/MED.0000000000000595. PMID: 33278129